29 July 2026
29 July 2026
The study will enrol around 1,000 participants at up to 100 sites across Canada, Europe, and the US.
The study met primary and secondary endpoints, with BEM/RZR showing statistical non-inferiority to sofosbuvir and velpatasvir.
The deal grants CORE Biomedicine rights to develop and commercialise cancer therapies.
The transaction is expected to close in the third quarter of 2026.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
